Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients

[1]  L. Tran,et al.  Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients , 2014, BMC Cancer.

[2]  Michael D. Brooks,et al.  Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. , 2014, The Journal of clinical investigation.

[3]  Jilong Yang,et al.  Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. , 2013, Surgical oncology.

[4]  K. S. Hall,et al.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1 , 2012, Neuro-oncology.

[5]  N. Warrington,et al.  Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors , 2012, Biology of Sex Differences.

[6]  T. de Ravel,et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.

[7]  G. Scott,et al.  Microarray Comparative Genomic Hybridization Detection of Copy Number Changes in Desmoplastic Melanoma and Malignant Peripheral Nerve Sheath Tumor , 2011, The American Journal of dermatopathology.

[8]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. , 2011, European journal of cancer.

[9]  Wei Zhang,et al.  Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment , 2011, Clinical Cancer Research.

[10]  R. Dubrow,et al.  Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007 , 2011, BMC Cancer.

[11]  C. Fischer,et al.  Sex-biased suppression of chemically induced neural carcinogenesis in congenic BDIX.BDIV-Mss4a rats. , 2011, Physiological genomics.

[12]  B. Scheithauer,et al.  Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor , 2011, Clinical Cancer Research.

[13]  M. Wallace,et al.  Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells , 2010, Cancer biology & therapy.

[14]  R. Dikshit,et al.  Malignant peripheral nerve sheath tumors: clinicopathological profile of 63 cases diagnosed at a tertiary cancer referral center in Mumbai, India. , 2010, Indian journal of pathology & microbiology.

[15]  K. S. Hall,et al.  Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[17]  S. Dry,et al.  Quantitative F18‐fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign , 2010, Cancer.

[18]  Andrew H. Beck,et al.  Genome‐wide transcriptome analyses reveal p53 inactivation mediated loss of miR‐34a expression in malignant peripheral nerve sheath tumours , 2010, The Journal of pathology.

[19]  S. Dry,et al.  PTEN dosage is essential for neurofibroma development and malignant transformation , 2009, Proceedings of the National Academy of Sciences.

[20]  C. Fischer,et al.  Genetic basis of sex-specific resistance to neuro-oncogenesis in (BDIX × BDIV) F2 rats , 2009, Mammalian Genome.

[21]  K. S. Hall,et al.  Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. , 2009, Neuro-oncology.

[22]  O. Myhre-Jensen,et al.  A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[23]  Karlyne M. Reilly,et al.  Chr 19A/J modifies tumor resistance in a sex- and parent-of-origin-specific manner , 2009, Mammalian Genome.

[24]  N. Freedman,et al.  Sex Disparities in Cancer Incidence by Period and Age , 2009, Cancer Epidemiology Biomarkers & Prevention.

[25]  P. Terrier,et al.  Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs , 2008, Sarcoma.

[26]  E. Petty,et al.  The role of steroid hormones in the NF1 phenotype: Focus on pregnancy , 2008, American journal of medical genetics. Part A.

[27]  N. Thomas,et al.  Germline and somatic NF1 gene mutation spectrum in NF1‐associated malignant peripheral nerve sheath tumors (MPNSTs) , 2008, Human mutation.

[28]  C. Hartmann,et al.  MMP-13, p53 in the Progression of Malignant Peripheral Nerve Sheath Tumors , 2007 .

[29]  M. Wallace,et al.  In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells , 2007, Molecular carcinogenesis.

[30]  R. Benigni.  Social sexual inequality and sex difference in cancer incidence. , 2007, Environmental research.

[31]  U. Bockmühl,et al.  Malignant peripheral nerve sheath tumors of the head and neck: Management of 10 cases and literature review , 2007, Head & neck.

[32]  S. Huson,et al.  The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs) , 2006, Human mutation.

[33]  R. Buchert,et al.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  J. Zeller,et al.  Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.

[35]  M. Watson,et al.  Gene Expression Profiling Reveals Unique Molecular Subtypes of Neurofibromatosis Type I‐associated and Sporadic Malignant Peripheral Nerve Sheath Tumors , 2004, Brain pathology.

[36]  S. Tripp,et al.  Malignant Peripheral Nerve Sheath Tumor: A Comparison of Grade, Immunophenotype, and Cell Cycle/Growth Activation Marker Expression in Sporadic and Neurofibromatosis 1-Related Lesions , 2003, The American journal of surgical pathology.

[37]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[38]  Theresa M. Wizemann,et al.  Exploring the biological contributions to human health: does sex matter? , 2001, Journal of women's health & gender-based medicine.

[39]  K. Leroy,et al.  Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. , 2001, Archives of dermatology.

[40]  J. McCann.  Gender differences in cancer that don't make sense--or do they? , 2000, Journal of the National Cancer Institute.

[41]  H. Taubert,et al.  Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. , 2000, Cancer letters.

[42]  R. Hughes,et al.  Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1 , 2000, Journal of neurology, neurosurgery, and psychiatry.

[43]  A. Ferrari,et al.  Malignant peripheral nerve sheath tumors in children: a single-institution twenty-year experience. , 1999, Journal of pediatric hematology/oncology.

[44]  F. Haseltine.  Does Sex Matter? , 1999, Science.

[45]  H. Taubert,et al.  Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant , 1999, Genes, chromosomes & cancer.

[46]  L. Dehner,et al.  p53 and Ki-67 Proliferating Cell Nuclear Antigen in Benign and Malignant Peripheral Nerve Sheath Tumors in Children , 1999, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[47]  M Super,et al.  A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.

[48]  A. Davis,et al.  Neurogenic sarcomas: experience at the University of Toronto. , 1998, Neurosurgery.

[49]  M. Bilsky,et al.  Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors , 1998, Cancer.

[50]  H. Inoue,et al.  A clinical analysis of malignant schwannoma. , 1997, Acta medica Okayama.

[51]  A. Pappo,et al.  Malignant peripheral nerve sheath tumors: The St. Jude Children's Research Hospital experience , 1995, Annals of Surgical Oncology.

[52]  J. Vauthey,et al.  Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): A 10-year experience , 1995, Annals of Surgical Oncology.

[53]  E. Abemayor,et al.  Malignant nerve sheath tumors of the head and neck: A combined experience from two university hospitals , 1991, The Laryngoscope.

[54]  R. Hruban,et al.  Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases , 1990, Cancer.

[55]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.

[56]  M. Enjoji,et al.  Malignant peripheral nerve‐sheath tumors (malignant schwannomas): An immunohistochemical study of 29 cases , 1985, The American journal of surgical pathology.

[57]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors with divergent differentiation , 1984, Cancer.

[58]  Takashi Nakajima,et al.  Malignant Peripheral Nerve Tumors: A Clinicopathological and Flectron Microscopic Study , 1984 .

[59]  J. Trojanowski,et al.  Malignant tumors of nerve sheath origin , 1980, Cancer.

[60]  F. Enzinger,et al.  Malignant schwannoma associated with von Recklinghausen's neurofibromatosis , 1979, Virchows Archiv A.

[61]  J. Beare.  A STUDY OF 43 CASES , 1976 .

[62]  G. Swapp,et al.  Neurofibromatosis in pregnancy , 1973, The British journal of dermatology.

[63]  A. Huvos,et al.  Malignant schwannoma. A Clinicopathologic Study , 1973, Cancer.

[64]  H. White.  Survival in malignant schwannoma. An 18‐year study , 1971, Cancer.

[65]  E. Soule,et al.  Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (von Recklinghausen's disease) , 1963, Cancer.

[66]  E. Soule,et al.  Primary malignant neoplasms of nerves (Malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (von Recklinghausen's disease) , 1963, Cancer.

[67]  R. H. Young,et al.  RECKLINGHAUSEN'S NEUROFIBROMATOSIS: CLINICAL MANIFESTATIONS IN THIRTY-ONE CASES , 1937 .

[68]  A. von Deimling,et al.  MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. , 2007, Neoplasia.

[69]  C. Fischer,et al.  Gender‐specific polygenic control of ethylnitrosourea‐induced oncogenesis in the rat peripheral nervous system , 2006, International journal of cancer.

[70]  J. Day.  Malignant schwannoma. , 2002, Journal of neurosurgery.

[71]  V. Muller.  Exploring the biological contributions to human health: does sex matter? , 2001, Journal of women's health & gender-based medicine.

[72]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[73]  F. Mitelman,et al.  Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. , 2000, The Journal of pathology.

[74]  T. Nakajima,et al.  Malignant peripheral nerve tumors: a clinicopathological and electron microscopic study. , 1984, Japanese journal of clinical oncology.